Techno Trends
Worldwide advancements and breakthroughs in pharmaceutical products and technology are thoroughly covered by Techno Trends. You may stay up to date with all the most recent pharmaceutical developments (product news and technological trends) taking place throughout the world.
Imaging Agent for Onco-Nano Cancer Surgery Receives Breakthrough Therapy Device Designation
Pegsitacianine, an imaging agent that aids in the detection of malignancies in the peritoneal cavity after cytoreductive surgery, including ovarian cancer, has been given the Breakthrough Therapy designation by the FDA. When not in use, pegsitacianine is fluorescently dark, but when acidic tumours are present...
Novel Inhibitor approved as a Breakthrough Therapy for the Treatment of Acute Leukemia
The U.S. Food and Drug Administration has given the oral menin inhibitor Revumenib a breakthrough therapy designation (BTD). Revumenib is used to treat patients with relapsed or refractory acute leukemia harboring a KMT2A arrangement (KMT2Ar)....
New Medication Efanesoctocog Alfa Discovered For Hemophilia Treatment
Sanofi and Sobi have formed a partnership to collaborate on the development and commercialization of efanesoctocog alfa (BIVV001), a treatment for haemophilia A, a rare and life-threatening bleeding disorder....
Eli Lilly's New Drug Mounjaro™ to Treat Type 2 Diabetes
Mounjaro™ (tirzepatide) injection, developed by Eli Lilly and Company, is a novel, dual-targeted therapy that has been demonstrated to enhance glycemic control in adult patients with type 2 diabetes. In people with type 2 diabetes, a once-weekly glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1...
Novel Mavacamten Discovered to Treat Obstructive Hypertrophic Cardiomyopathy (oHCM)
LianBio, discovered novel Mavacamten for the treatment of patients with obstructive hypertrophic cardiomyopathy (oHCM). Mavacamten is a first-in-class, oral, allosteric modulator of cardiac myosin which is under investigation for the treatment of excessive cardiac contractility. It lowers the risk of cardiac muscle contractility by restricting...
First-of-its-Kind Digital Therapeutic BNT200 Discovered
Blue Note Therapeutics discovered first-of-its-kind prescription-only digital therapeutic BNT200 for the treatment of anxiety and depressive symptoms in adults patients with acute myeloid leukemia (AML) hospitalised for a regimen of high-intensity induction chemotherapy. BNT200 is a software as a medical device (SaMD) designed t0 treat anxiety and depressive...
Breakthrough CardiAMP Cell Therapy System Discovered for Heart Failure
BioCardia®, Inc revolutionizes heart failure treatment with the groundbreaking CardiAMP® Cell Therapy System. By harnessing the patient's own bone marrow cells and delivering them to the heart through a minimally invasive, catheter-based procedure, CardiAMP...
Novel Patho-Seq Assay Discovered for the Detection of Bacteria
Pathogenomix Inc, discovered novel Patho-Seq assay. Patho-Seq uses Next Generation Sequencing for the rapid identifaction of bacteria presented in human sample through dangerous and life-threatening infections. Patho-Seq detects hundreds of clinically relevant bacteria collected from wide...
Telisotuzumab Vedotin (Teliso-V) Developed for the Treatment of Non-Small Cell Lung Cancer
AbbVie developed Telisotuzumab Vedotin (Teliso-V) an investigational antibody-drug conjugate (ADC), to treat patients with non-small cell lung cancer (NSCLC). (Teliso-V) is used to treat patients with advanced/metastatic epidermal growth factor receptor (EGFR) wild type, nonsquamous non-small cell lung cancer (NSCLC) consisting...
New Patritumab Deruxtecan (HER3-DXd) Discovered for the Treatment of Metastatic EGFR-Mutated Non-Small Cell Lung Cancer
Daiichi Sankyo discovered new patritumab deruxtecan to treat patients with metastatic or locally advanced EGFR-mutated non-small cell lung cancer (NSCLC). Patritumab deruxtecan (HER3-DXd), is the firt irst-in-class HER3 directed antibody drug conjugate (ADC), applicable with third-generation tyrosine kinase inhibitor...
